

Title (en)  
NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS

Title (de)  
NEUROBLASTOMBEHANDLUNG MIT TAUROLIDIN-HYDROLYSEPRODUKTEN

Title (fr)  
TRAITEMENT DU NEUROBLASTOME AVEC DES PRODUITS D'HYDROLYSE DE TAUROLIDINE

Publication  
**EP 3843746 A4 20221019 (EN)**

Application  
**EP 19856239 A 20190828**

Priority  
• US 201862723618 P 20180828  
• US 2019048592 W 20190828

Abstract (en)  
[origin: WO2020047113A1] Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically- resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. The efficacy in rodent model is superior to the efficacy in cell culture. This invention relates to the use of taurolidine hydrolysis products (tauraltam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in juvenile mammals.

IPC 8 full level  
**A61K 31/54** (2006.01); **A61K 31/541** (2006.01); **A61K 31/549** (2006.01); **A61K 45/06** (2006.01)

CPC (source: EP KR)  
**A61K 9/0019** (2013.01 - EP KR); **A61K 9/5146** (2013.01 - KR); **A61K 9/5153** (2013.01 - KR); **A61K 31/18** (2013.01 - EP KR); **A61K 31/549** (2013.01 - EP KR); **A61K 45/06** (2013.01 - EP KR); **A61K 47/10** (2013.01 - EP KR); **A61K 47/60** (2017.08 - KR); **A61P 35/00** (2018.01 - KR); **A61K 2300/00** (2013.01 - KR)

C-Set (source: EP)  
1. **A61K 31/549 + A61K 2300/00**  
2. **A61K 31/18 + A61K 2300/00**

Citation (search report)  
• [I] US 2005096314 A1 20050505 - PFIRRMANN ROLF W [CH]  
• [I] ESCHENBURG GEORG ET AL: "Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells", GENES & CANCER, vol. 5, no. 11-12, 9 October 2014 (2014-10-09), pages 460 - 469, XP055885452, DOI: 10.18632/genesandcancer.36  
• [I] ANONYMOUS: "Cormedix Inc. announces agreement with nanoproteagen for its proprietary nanoparticle technology, Nanopro TM, in combination with CRMD-005 for pediatric neuroblastoma", INTERNET CITATION, 11 May 2016 (2016-05-11), XP002792142, Retrieved from the Internet <URL:http://www.cormedix.com/cormedix-inc-announces-agreement-with-nanoproteagen-for-its-proprietary-nanoparticle-technology-nanopro-in-combination-with-crmd-005-for-pediatric-neuroblastoma-2/> [retrieved on 20190617]  
• [I] LUCKERT CHRISTIAN ET AL: "Taurolidine Specifically Inhibits Growth of Neuroblastoma Cell Lines In Vitro", JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, vol. 36, no. 4, 1 May 2014 (2014-05-01), US, pages e219 - e223, XP055958541, ISSN: 1077-4114, Retrieved from the Internet <URL:http://dx.doi.org/10.1097/MPH.0000000000000149> DOI: 10.1097/MPH.0000000000000149  
• [A] GONG LI ET AL: "The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers", THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 6, 1 June 2007 (2007-06-01), US, pages 697 - 703, XP055958727, ISSN: 0091-2700, Retrieved from the Internet <URL:http://dx.doi.org/10.1177/0091270007299929> DOI: 10.1177/0091270007299929  
• [A] STENDEL RUEDIGER ET AL: "Pharmacokinetics of Taurolidine following Repeated Intravenous Infusions Measured by HPLC-ESI-MS/MS of the Derivatives Tauraltame and Taurinamide in Glioblastoma Patients .:", CLINICAL PHARMACOKINETICS., vol. 46, no. 6, 1 January 2007 (2007-01-01), NZ, pages 513 - 524, XP055945305, ISSN: 0312-5963, Retrieved from the Internet <URL:http://dx.doi.org/10.2165/00003088-200746060-00005> DOI: 10.2165/00003088-200746060-00005  
• [I] BUCHHOLZ MARIE: "GMS | 130. Kongress der Deutschen Gesellschaft für Chirurgie | Effectivity and toxicity of Tauraltam (TRLT) as anti-neoplastic agent in malignant tumor cells - in vitro study of pancreatic and colon cancer cell lines", 3 May 2013 (2013-05-03), pages 1 - 2, XP055959034, Retrieved from the Internet <URL:https://www.egms.de/static/de/meetings/dgch2013/13dgch861.shtml> [retrieved on 20220908]  
• See also references of WO 2020047113A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2020047113 A1 20200305**; AU 2019330954 A1 20210422; CA 3111057 A1 20200205; CN 113347976 A 20210903; EP 3843746 A1 20210707; EP 3843746 A4 20221019; JP 2021535163 A 20211216; KR 20210050544 A 20210507

DOCDB simple family (application)  
**US 2019048592 W 20190828**; AU 2019330954 A 20190828; CA 3111057 A 20190828; CN 201980071416 A 20190828; EP 19856239 A 20190828; JP 2021511544 A 20190828; KR 20217008971 A 20190828